

What is claimed is:

1. A composition comprising glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol in amounts together effective to treat chronic liver disease, chronic HCV infection, or NASH in a subject.
- 5 2. The composition of claim 1, wherein the amount of glycyrrhizin is in the range of 1,000 to 1,500 mg.
3. The composition of claim 1, wherein the amount of schisandra extract is in the range of 1,500 to 3,000 mg.
4. The composition of claim 1, wherein the amount of ascorbic acid is in the range of
10 500 to 10,000 mg.
5. The composition of claim 1, wherein the amount of L-glutathione is in the range of 50 to 1,000 mg.
6. The composition of claim 1, wherein the amount of silymarin is in the range of 80 to 1,000 mg.
- 15 7. The composition of claim 1, wherein the amount of lipoic acid is in the range of 150 to 1,200 mg.
8. The composition of claim 1, wherein the amount of d-alpha-tocopherol is in the range of 200 to 1,600 iu.
9. The composition of claim 1, wherein the amount of glycyrrhizin is in the range of
20 1,000 to 1,500 mg, the amount of schisandra extract is in the range of 1,500 to 3,000 mg, the amount of ascorbic acid is in the range of 500 to 10,000 mg, the amount of L-glutathione is in the range of 50 to 1,000 mg, the amount of silymarin is in the range of 80 to 1,000 mg, the amount of lipoic acid is in the range of 150 to 1,200 mg, and the amount of d-alpha-tocopherol is in the range of 200 to 1,600 iu.
- 25 10. The composition of claim 1 in capsule form.

11. A composition comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex in amounts together effective to treat chronic liver disease, chronic HCV infection, or NASH in a subject.
12. The composition of claim 11, wherein the amount of glycyrrhizin is in the range of 10 to 500 mg.
13. The composition of claim 11, wherein the amount of ascorbic acid is in the range of 1,000 to 20,000 mg.
14. The composition of claim 11, wherein the amount of L-glutathione is in the range of 250 to 1,500 mg.
15. The composition of claim 11, wherein the amount of vitamin B-complex is in the range of 0.1 to 100 ml.
16. The composition of claim 11, wherein the amount of glycyrrhizin is in the range of 10 to 500 mg, the amount of ascorbic acid is in the range of 1,000 to 20,000 mg, the amount of L-glutathione is in the range of 250 to 1,500 mg, and the amount of vitamin B-complex is in the range of 0.1 to 100 ml.
17. A syringe containing the composition of claim 11.
18. A method for treating chronic liver disease, chronic HCV infection or NASH in a subject comprising administering to the subject an amount of the composition of claim 1 effective to treat chronic liver disease, chronic HCV infection or NASH.
19. The method of claim 18, wherein the composition of claim 1 is administered to the subject orally.
20. A method for treating chronic liver disease, chronic HCV infection or NASH in a subject comprising administering to the subject an amount of the composition of claim 11 effective to treat chronic liver disease, chronic HCV infection or NASH.
21. The method of claim 20, wherein the composition of claim 11 is parenterally administered to the subject.

22. The method of claim 20, wherein the composition of claim 11 is administered to the subject by infusion.

23. A method for treating chronic liver disease, chronic HCV infection or NASH in a subject comprising administering to the subject an amount of

5 (a) a first composition comprising glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol; and

(b) a second composition comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex,

said amount being effective to treat chronic liver disease, chronic HCV infection or

10 NASH.

24. The method of claim 23, wherein the first composition is administered to the subject orally.

25. The method of claim 23 or 24, wherein the second composition is parenterally administered to the subject.

15 26. The method of claim 25, wherein the second composition is administered to the subject by infusion.

27. A method for treating chronic liver disease, chronic HCV infection or NASH in a subject comprising administering to the subject glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol, in amounts together
20 effective to treat chronic liver disease, chronic HCV infection or NASH.

28. The method of claim 27, wherein 1,000 to 1,500 mg of glycyrrhizin are administered to said subject.

29. The method of claim 27, wherein 1,000 to 3,000 mg of schisandra extract are administered to said subject.

25 30. The method of claim 27, wherein 50 to 10,000 mg of ascorbic acid are administered to said subject.

31. The method of claim 27, wherein 50 to 1,000 mg of L-glutathione are administered to said subject.

32. The method of claim 27, wherein 80 to 1,000 mg of silymarin are administered to said subject.
33. The method of claim 27, wherein 100 to 1,200 mg of lipoic acid are administered to said subject.
- 5 34. The method of claim 27, wherein 200 to 1,600 iu of d-alpha-tocopherol are administered to said subject.
35. The method of claim 27, wherein 1,000 to 1,500 mg of glycyrrhizin, 1,000 to 3,000 mg of schisandra extract, 50 to 10,000 mg of ascorbic acid, 50 to 1,000 mg of L-glutathione, 80 to 1,000 mg of silymarin, 100 to 1,200 mg of lipoic acid, and 200 to 1,600 iu of d-alpha-
10 tocopherol are administered to said subject.
36. The method of claim 27, wherein the glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol are administered to the subject orally.
37. A method for treating chronic liver disease, chronic HCV infection or NASH in a
15 subject comprising administering to the subject glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, in amounts together effective to treat chronic liver disease, chronic HCV infection or NASH.
38. The method of claim 37, wherein 10 to 500 mg of glycyrrhizin are administered to said subject.
- 20 39. The method of claim 37, wherein 1,000 to 20,000 mg of ascorbic acid are administered to said subject.
40. The method of claim 37, wherein 250 to 1,500 mg of L-glutathione are administered to said subject.
41. The method of claim 37, wherein 0.1 to 100 ml of vitamin B-complex are
25 administered to said subject.
42. The method of claim 37, wherein 10 to 500 mg of glycyrrhizin, 1,000 to 20,000 mg of ascorbic acid, 250 to 1,500 mg of L-glutathione, and 0.1 to 100 ml of vitamin B-complex are administered to said subject.

43. The method of claim 37, wherein the glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex are parenterally administered to the subject.
44. The method of claim 43, wherein the glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex are administered to the subject by infusion.
- 5 45. A method for treating chronic liver disease, chronic HCV infection or NASH in a subject comprising: 7
- (a) administering to the subject orally each day for 20 weeks:
- 10 (i) 1,000 to 1,500 mg of glycyrrhizin;
- (ii) 1,500 to 3,000 mg of schisandra extract;
- (iii) 500 to 10,000 mg of ascorbic acid;
- (iv) 50 to 1,000 mg of L-glutathione;
- (v) 80 to 1,000 mg of silymarin;
- (vi) 150 to 1,200 mg of lipoic acid
- (vii) 200 to 1,600 i.u. of d-alpha-tocopherol; and
- 15 (b) parenterally administering to the subject twice a week for 10 weeks:
- (i) 10 to 500 mg of glycyrrhizin;
- (ii) 1,000 to 20,000 mg of ascorbic acid;
- (iii) 250 to 1,500 mg of L-glutathione; and
- (iv) 0.1 to 100 ml of vitamin B-complex.
- 20 46. The method of claim 45, wherein the level of free oxygen radicals in the subject is reduced.
47. The method of claim 45, wherein the level of antioxidants in the subject is increased.
48. The method of claim 45, wherein the level of adducts in the subject is reduced.
49. The method of claim 45, wherein the level of liver enzymes in the subject is
- 25 normalized.
50. The method of claim 45, wherein the level of cirrhosis in the subject is reduced.
51. The method of claim 45, wherein the level of fibrosis, lobular hepatitis or periportal bridging necrosis in the subject is reduced.

52. A kit comprising:
- 5 (a) a first container comprising a first composition comprising glycyrrhizin, schisandra extract, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol, in amounts together effective to treat chronic liver disease, chronic HCV infection or NASH; and
- (b) a second container comprising a second composition comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, in amounts together effective to treat chronic liver disease, chronic HCV infection or NASH.
53. The kit of claim 52, wherein the container is a syringe.
- 10 54. A kit comprising a container comprising the composition of claim 1.
55. A kit comprising a container comprising the composition of claim 11.
56. A kit comprising a container comprising
- 15 (a) a first syringe comprising glycyrrhizin;
- (b) a second syringe comprising ascorbic acid;
- (c) a third syringe comprising L-glutathione; and
- (d) a fourth syringe comprising vitamin B-complex,
- in amounts together effective to treat chronic liver disease, chronic HCV infection or NASH.